WB
WB analysis using CDKN2A/P16-INK4A Monoclonal antibody.IHC
IHC staining of Human Breast Cancer(Her2+;ER-;PR-) using CDKN2A/P16-INK4A Monoclonal antibody.| 抗体类型 | Primary Antibodies |
|---|---|
| 免疫原 | Recombinant human P16-INK4A protein. |
| 克隆性 | Monoclonal |
| 同种型 | IgG2a |
| 宿主 | Mouse |
| 已测试的应用 | IHCWB |
| 物种反应性 | Human |
| 浓度 | 1mg/ml |
| 纯化 | Protein A |
| 基因名称 | CDKN2A |
| 基因别名 | ARF; MLM; P14; P16; P19; CAI2; CMM2; INK4; MTS1; TP16; CDK4I; CDKN2; INK4A; MTS-1; P14ARF; P19ARF; P16INK4; P16INK4A |
| 基因全称 | cyclin dependent kinase inhibitor 2A |
| 基因简介 | This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012] |
| 蛋白别名 | p16, p16 INK4, P16 INK4A, p16-INK4, p16INK4A |
| 分子量 | 16 kDa |
| 应用稀释比 |
WB:1:1000-1:5000 IHC:1:2000-1:8000 |
| 亚细胞定位 | Cytoplasm,Nucleus. |
| 产品形态 | Liquid |
| 缓冲液 | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| 保存条件 | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20°C storage. |
请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法：
比如您的给药剂量是10 mg/kg，每只动物体重20 g，给药体积100 μL， 一共给药动物10只，您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O， 那么您的工作液浓度为2 mg/mL。
母液配置方法：2 mg 药物溶于 100 μL DMSO （ 母液浓度为 20 mg/mL ）, 如您需要配置的浓度超过该产品的溶解度，请先与我们联系。
体内配方的制备方法： 取 100 μL DMSO 母液， 添加 400 μL PEG300 混匀澄清， 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例，并不是具体某个化合物的推荐配制方式，请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如： DMSO， PEG300， PEG400， Tween 80， SBE-β-CD， 玉米油等， 均可在诺渊网站点击购买。
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL Saline/PBS/ddH2O，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
